Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · HARROW, INC. (HROW)

Harrow closes TYRVAYA acquisition for $30 million cash, up to $100 million total

Neutral Impact 3 of 5 m&a Written later

Harrow completed its acquisition of worldwide rights to TYRVAYA nasal spray from Viatris on October 1, 2026, excluding Japan, paying $30 million in cash at closing funded from cash on hand. The company may also pay up to $70 million in contingent milestone payments tied to TYRVAYA net sales, and it expects TYRVAYA to contribute more than $30 million in revenue in 2027.

Key points

  • Closing payment of $30.0 million in cash, funded with cash on hand, with the price fixed after the net working capital adjustment was eliminated
  • Up to $70.0 million in contingent milestone payments tied to net sales over twelve-month periods ending on or before December 31, 2029
  • Viatris keeps Japanese commercial rights and will pay Harrow tiered royalties on Japanese net sales
  • Harrow expects approximately 40 Viatris personnel to join its Ocular Surface commercial team in the fourth quarter of 2026

The filing

CompanyHARROW, INC. (HROW)
Form8-K, current report
Filed with the SECOct 5, 2026, 7:32 AM ET
Accession number0001628280-26-064749

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.